Chan Henry Lee - 30 Sep 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship: SVP, General Counsel
Issuer ticker: ONC
Reported as of: 30 Sep 2026
Net transaction value: -$418,125
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:53:14 UTC
Prior SEC filing: 13 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Frank Collazo, as Attorney-in-Fact

Key filing fact

Chan Henry Lee filed Form 4 for BeOne Medicines Ltd. (ONC) on 02 Oct 2026.

Key facts

This page summarizes Chan Henry Lee's Form 4 filing for BeOne Medicines Ltd. (ONC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Oct 2026, 16:53.

Change

Previous filing in this sequence was filed on 13 Aug 2026.
Current net transaction value: -$418,125.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001980648 Primary reporting owner

Lee Chan Henry

Relationship: SVP, General Counsel
Address: C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND
Signature: /s/ Frank Collazo, as Attorney-in-Fact
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

American Depositary Shares

Sale

Transaction value: $418,125
Shares: -1,115
Change %: -100%
Price: $375.00
Shares after: 0
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F2, F3

ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 311,324
Date: 30 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Includes 507 ordinary shares acquired pursuant to the Company's 2018 Employee Share Purchase Plan, as amended from time to time.

Footnote F2

Each American Depositary Share represents 13 Ordinary Shares.

Footnote F3

The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.